WO2000008132A1 - Prolonged culturing of avian primordial germ cells using specific growth factors and use thereof - Google Patents
Prolonged culturing of avian primordial germ cells using specific growth factors and use thereof Download PDFInfo
- Publication number
- WO2000008132A1 WO2000008132A1 PCT/US1999/017385 US9917385W WO0008132A1 WO 2000008132 A1 WO2000008132 A1 WO 2000008132A1 US 9917385 W US9917385 W US 9917385W WO 0008132 A1 WO0008132 A1 WO 0008132A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pgcs
- avian
- cells
- culture
- chimeric
- Prior art date
Links
- 241000271566 Aves Species 0.000 title claims abstract description 91
- 239000003102 growth factor Substances 0.000 title claims description 36
- 210000004602 germ cell Anatomy 0.000 title claims description 25
- 238000012258 culturing Methods 0.000 title claims description 20
- 230000002035 prolonged effect Effects 0.000 title claims description 7
- 241000287828 Gallus gallus Species 0.000 claims abstract description 47
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract description 26
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims abstract description 23
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims abstract description 23
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract description 20
- 238000003822 preparative gas chromatography Methods 0.000 claims abstract 19
- 210000004027 cell Anatomy 0.000 claims description 81
- 238000000034 method Methods 0.000 claims description 46
- 210000002257 embryonic structure Anatomy 0.000 claims description 38
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 22
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 22
- 235000013601 eggs Nutrition 0.000 claims description 17
- 210000001161 mammalian embryo Anatomy 0.000 claims description 15
- 239000001963 growth medium Substances 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical group 0.000 claims description 8
- 102000013275 Somatomedins Human genes 0.000 claims description 6
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 210000000709 aorta Anatomy 0.000 claims description 5
- 238000012423 maintenance Methods 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 210000003462 vein Anatomy 0.000 claims description 3
- 210000001172 blastoderm Anatomy 0.000 claims description 2
- 239000003104 tissue culture media Substances 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims 1
- 235000013330 chicken meat Nutrition 0.000 abstract description 38
- 230000009261 transgenic effect Effects 0.000 abstract description 25
- 238000004519 manufacturing process Methods 0.000 abstract description 20
- 241000286209 Phasianidae Species 0.000 abstract description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 abstract 1
- 102100020880 Kit ligand Human genes 0.000 abstract 1
- 101710177504 Kit ligand Proteins 0.000 abstract 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 abstract 1
- 210000002149 gonad Anatomy 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 238000012546 transfer Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 230000007774 longterm Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 238000001890 transfection Methods 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 6
- 230000001177 retroviral effect Effects 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 210000003746 feather Anatomy 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000001638 lipofection Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000011435 rock Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 230000012447 hatching Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 241000287436 Turdus merula Species 0.000 description 2
- 230000002927 anti-mitotic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 241000713826 Avian leukosis virus Species 0.000 description 1
- -1 BFGF Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001379910 Ephemera danica Species 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010091205 Libid Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 101100407657 Mus musculus Pgc gene Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 102000055151 human KITLG Human genes 0.000 description 1
- 102000046645 human LIF Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0611—Primordial germ cells, e.g. embryonic germ cells [EG]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
Definitions
- the present invention provides a novel method for maintaining avian primordial germ cells (PGCs), in particular chicken PGCs, for prolonged periods in tissue culture.
- PGCs primordial germ cells
- These PGCs can be used for the insertion of desired DNA sequences, e.g., human genes.
- PGCs, and transgenic PGCs derived therefrom, may 0 be used to produce chimeric birds, in particular chimeric chickens.
- the modification of the genome of farm animal species is an 5 area which has been actively pursued, with varying degrees of success, for the past two decades.
- such research has been focused toward generating transgenic pigs, cows, and chickens.
- the majority of the available transgenic animals have been generated by the direct microinjection of single cell embryos with DNA constructs harboring the gene of interest.
- 0 microinjection techniques have been successful, such methods are disadvantageous in that they are costly and often suffer from low efficiency.
- ES embryonic stem
- PSCs primordial germ cells
- the first approach which comprises manipulation of the genome before lay has yielded mixed and/or inefficient results.
- the infection of oocytes in the ovary (Shuman, and Shoffner, Poultry Sci., 65:1437-1494 (1986) and pre- incubation of sperm with plasmid DNA (Gruenbaum et al., J. Cell. Biochem Supp. , 15:194 (1991) were inefficient and have not been repeated.
- the transfection of sperm cells with a plasmid construct by lipofection has been demonstrated (Squires and Drake, Anim. Biotech., 4:71-78 1993). However, germ line transmission was not reported.
- Previous PGC culturing methods have included the use of growth factor, in particular LIF or IGF-I. However, as noted, such methods have not been able to provide for prolonged culturing periods, a prevalent concern as it would facilitate the production of transgenic PGCs.
- both ES and PGC cells have been successfully used to generate chimeras by infection of such cells with replication competent and incompetent retroviral vectors.
- freshly obtained blastodermal cells have been injected into recipient embryos, resulting in birds with chimeric gonads (Carsience et al., DeveL, 117:669-675 1993)).
- Blastodermal cells can be efficiently transfected by lipofec- tion and then transferred into recipient embryos.
- germ line transmission of transfected cells has not been reported.
- An alternative route to the production of ES cells comprises PGCs.
- Procedures for the isolation and transfer of PGCs from donor to recipient embryos have been developed and have successfully generated chimeric chicken with germ line transmission of the donor genotype (Vick et al., London Ser. B, 251 :179-182 (1993), Tajima et al, Theriogenology, 40:509-519 (1993)).
- PGCs have been cryopreserved and later thawed to generate chimeric birds (Naito et al., J. Reprod. Fertil, 102:321-325 (1994)).
- this system is very labor intensive and only yields, on average, only 50 to 80 PGCs per embryo.
- PPCs primordial germ cells
- transgenic chimeric avians preferably Gallinacea and most preferably chickens
- transgenic chimeric avians for the production of heterologous protein(s) encoded by a nucleic acid sequence contained in cells introduced therein, preferably by recovery of such protein(s) from the eggs of such transgenic chimeric avians, in particular transgenic chimeric chickens.
- proteins may be obtained from the chimeric bird directly, e.g., isolated from the blood or other tissues.
- the present invention provides a novel method for maintaining avian (chicken) primordial germ cells (PGCs) in tissue culture for prolonged periods, i.e., for at least 14 days, more preferably at least 25 days, and ideally indefinitely.
- avian chicken
- primordial germ cells PLCs
- LIF leukemia inhibitory factor
- bFGF basic fibroblast growth factor
- SCF stem cell factor
- IGF-I insulin-like growth factor
- these PGCs should be useful for the production of transgenic avian PGCs, which can be used to produce transgenic chimeric avians. It is expected that these transgenic chimeric avians will be useful for recovery of heterologous proteins, which preferably can be recovered directly from the eggs of such chimeric transgenic avians. For example, such avians can be used for the production and recovery of therapeutic proteins and other polypeptides.
- the present invention obviates the problems associated with previous avian PGC culturing methods which did not enable such PGCs to be maintained in tissue culture for periods longer than about five days.
- the present inventors have surprisingly discovered that avian PGCs, preferably Gallinacea PGCs, and most preferably chicken PGCs can be maintained in tissue culture for prolonged periods, in at least 14 days, more preferably at least 25 days, and preferably longer, by the use of culture medium which contains at least the following four growth factors: leukemia inhibiting factor (LIF), stem cell factor
- the present culturing method comprises the following steps: (i) isolating PGCs from donor avian embryos; and (ii) culturing said isolated avian PGCs in a culture medium containing relative amounts of LIF, bFGF, SCF and IGF-I effective to promote their proliferation, for a prolonged time, i.e., at least 14 days, in tissue culture. Prolonged periods, as defined above, refers to a culture period 14 days or longer.
- the present inventors elected to isolate avian PGCs from chicken eggs which had been incubated for about 53 hours (stage 12-14 of embryonic development), removal of embryos therefrom, collection of embryonic blood from the dorsal aorta thereof, and transferral thereof to suitable cell culture medium (Ml 99 medium). These PGCs were then purified by ficoll density centrifugation, and resuspended in lO ⁇ l of the growth factor containing culture medium of the present invention.
- Other methods for isolating PGCs are known and may alternatively be used.
- the isolated PGCs are then counted and separated manually (e.g., using a pipette). Thereafter, PGCs collected from these different avian embryos are pooled (to increase PGC numbers) and incubated in the subject growth factor containing medium.
- This culture medium hereinafter referred to as "complete” medium contains LIF, bFGF, SCF and IGF-I as well as other substituents typically comprised in PGC and embryonic stem cell medium. More specifically, the subject "complete" medium will preferably comprise ⁇ -MEM, a well known commercially available cell growth medium to which has been added the above four growth factors and which additionally includes 10% fetal calf serum, 2 mM L-glutamine, 0.56% antibiotic/antimitotic, 34.56 mM 2- ⁇ mercaptoethanol, 1.0 U/ ⁇ l LIF, 40.0 pg/ ⁇ l bFGF, 60.0 pg/ ⁇ l IGF-I and 80.0 pg/ ⁇ l of SCF.
- ⁇ -MEM a well known commercially available cell growth medium to which has been added the above four growth factors and which additionally includes 10% fetal calf serum, 2 mM L-glutamine, 0.56% antibiotic/antimitotic, 34.56 mM 2- ⁇ mercaptoethanol
- these growth factors can be varied with PGCs being successfully maintained in tissue culture.
- the respective amounts of these growth factors may be increased with no adverse effects.
- these preferred amounts may vary, e.g., if PGCs of other avians are cultured.
- ⁇ -MEM tissue culture medium
- other media may be substituted therefor, provided that these four essential growth factors are also present.
- Applicants particularly contemplate modification of the subject "complete media" to eliminate fetal calf serum, because of its undefined and variable composition.
- feeder cells may also be useful.
- fibroblasts preferably avian fibroblasts, and most preferably Gallinacea fibroblasts (still more preferably chicken fibroblasts)
- these feeder cells may be transfected with genes encoding these growth factors, thereby eliminating the need for the exogenous addition of these factors during culturing. Essentially, the cells will provide a continual source of these growth factors.
- the amounts of these factors refer to relative amounts thereof effective to enable prolonged culturing of avian PGCs, preferably Gallinacea PGCs, and most preferably chicken or turkey PGCs, for prolonged periods in tissue culture.
- the relative amounts of these growth factors will fall within the following ranges: LIF 0.1 U/ ⁇ l to 100.0 U/ ⁇ l, more preferably 1.0 to 10.0 U/ ⁇ l and most preferably 1.0 to 2.0 U/ ⁇ l;
- these preferred ranges may vary, e.g., if ⁇ -MEM is substituted by another growth medium and if other types of avian PGCs are cultured.
- these PGCs can be maintained for long periods in culture with the successful production of chimeric avians.
- the cells have been maintained in tissue culture for up to about 4 months, with apparently no adverse effects.
- cells of up to 25 days have been tested for their ability to effectively colonize avian embryonic gonads and produce chimeric birds.
- these cells can be cultured indefinitely, with retention of the ability to produce chimeric birds.
- PGCs will be transferred into recipient avian embryos according to the methods disclosed in the example while follows. Thereafter, successful chimera production is evaluated based on migration and colonization of PGCs in the gonads, retention of PGC phenotype, or by looking for the presence of donor PGCs in gonads after hatching and breeding.
- the inventors selected genotypes which are easily followed which affect coloration. Donor birds were white broiler type and recipient birds were black feathered birds, respectively, having specific potential genotypes.
- the putative chimeras were black feathered and produced black/white progeny when mated with black birds. Thereby, successful chimeras were demonstrated based on the production of black/white feathered progeny produced after mating the putative chimeric bird with another black feathered bird.
- Bar Rock birds were used as recipients, and white feathered birds used as donors. Putative chimeric birds were demonstrated based on the production of white feathered progeny having some barred feathers.
- the subject method should be applicable for introducing any desired trait by chimerization. This will, of course, depend on the genotypic properties of the transferred PGCs.
- a significant application of the subject PGCs which can be maintained in culture for long periods, is for the production of chimeric avians.
- This will be accomplished by introducing a desired DNA sequence into the cultured PGCs.
- Means for introducing DNAs into recipient cells are known and include lipofection, transfection, microinjection, transformation, microprojectic techniques, etc.
- the present inventors initially elected to introduce a vector containing a reporter gene by lipofection.
- transiently transfected PGCs were produced, a stable transfected cell line has not, as yet, been isolated. However, it is expected that this can be accomplished by known techniques using the subject PGCs.
- a DNA will be introduced that encodes a desired gene, e.g., therapeutic polypeptide, growth factor, enzyme, etc, under the regulatory control of sequences operable in avians.
- these regulatory sequences will be of eukaryotic origin, most preferably avian, e.g., chicken regulatory sequences. Promoters operable in avian cells, e.g., derived from avian genes or viruses are known in the art.
- a stable cell line which produces the desired protein will be isolated and used for chimera production.
- the introduced DNA contain a marker DNA, the expression of which is easily detected, to more easily identify cells containing the inserted DNA.
- selectable markers include ⁇ -lactamase, ⁇ -galactosidase, neomycin phosphotranspherase, etc.
- transgenic chimeric avians Injection of the resultant transgenic PGCs into avian embryos will then result in the production of transgenic chimeric avians.
- the desired protein will then be recovered from the eggs of these transgenic avians, thereby providing a continual supply of the protein.
- the protein can be recovered from chimeric birds directly, e.g., isolated from the systemic circulatory system.
- E/E and I/I broiler type chickens have been used as donors of PGCs to develop the long term PGC culture system. Two types of bird were used as recipient embryos, a dominant black feather (El- and i/i) chicken line and a Bar Rock (E/E and i/i) line. Dominant black birds injected with white broiler (WB) type PGCs are referred as E/-(WB) and Bar Rock birds injected with white broiler type PGCs are referred as BR(WB).
- E/-(WB) and Bar Rock birds injected with white broiler type PGCs are referred as BR(WB).
- PGCs were collected from the dorsal aorta with a fine micropipette as described by Naito et al, Mol. Reprod. Dev., 37:167-171 (1994). PGCs from 20 embryos were pooled in Hanks' solution supplemented with 10% fetal bovine serum and concentrated by Ficoll density gradient centrifugation (Naito et al, Mol. Reprod. Dev., 39:153-171 1994). PGCs were counted and distributed in 10 ⁇ l drops of culture medium (DMEM, containing differing amounts of growth factors) at about 100 PGCs per drop. Culture drops were overlaid with sterile light mineral oil. Injection of PGCs into recipient embryos
- DMEM culture medium
- Stage 14-15 embryos were used as recipient embryos. After placing the egg on an appropriate surface, time was allowed for the developing embryo to position itself on the upper side of the resting egg. A small, about 10 mm “window” or less in the shell was made with a fine forceps. The embryo was brought close to the surface by adding a mixture of phosphate buffer saline with 4% antibiotics. After accommodating the embryo to visualize its heart, the marginal vein and/or dorsal aorta could be easily identified. Two hundred donor PGCs in 2 ⁇ l of media containing 0.04% trypan blue were taken into a micropipette. PGCs were injected into the dorsal aorta of the recipient embryo.
- PGCs were stained with Dil fluorescent stain. Embryos were collected after 24 hours of transfer, placed on a petri-dish and observed under an inverted microscope equipped for epi-fluorescent analysis.
- PGC culture conditions Several concentrations of human leukemia inhibitory factor (Lif), human basic fibroblast growth factor (bFGF), human insulin-like growth factor (IGF-I) and human stem cell factor (SCF) have been tested. Likewise, mitomycin treated chicken fibroblast and mouse STO cell feeder layers were tested. PGCS LONG-TERM CELL CULTURE MEDIUM
- the complete cell culture medium comprised the following substituents: ⁇ -MEM (BioWhittaker, Walkersville, MD, Cat# 12- 169F), 10% fetal calf serum (Hyclone, Logan, UT, Cat# 30070.03), 2 mM L- glutamine (Sigma, St. Louis, MO, Cat# G7513), 0.48% antibiotic/antimycotic (Signa, St.
- LIF leukemia inhibitory factor
- b-FGF basic fibroblast growth factor
- IGF-I insulin like growth factor
- SCF stem cell factor
- the final medium contains now the following growth factor concentrations: 0.0125 U/ ⁇ l of leukemia inhibitory factor (LIF), 0.5 pg/ ⁇ l of basic fibroblast growth factor (bFGF), 1.125 pg/ ⁇ l of insulin like growth factor-I (IGF-I) and 8.0 pg/ ⁇ l of stem cell factor (SCF).
- LIF leukemia inhibitory factor
- bFGF basic fibroblast growth factor
- IGF-I insulin like growth factor-I
- SCF stem cell factor
- a particularly preferred culture medium for maintaining primordial germ cell cultures will comprise the same substituents as above wherein the amounts of LIF, IGF-I, SCF and bFGF are as follows:
- PGCs were found to form large, dense, loosely adherent clumps of cells (some of the clumps have several hundreds of cells in them) within 3 to 4 days after collection. At the end of 7 days the clumps start to have large numbers of dead cells and cellular debris surrounding them. PGC clumps survive up to four weeks before they become cell monolayers. At weeks 1, 2 and 3, clumps have been dissociated, stained with a vital dye Dil and transferred into recipient embryos. At all three time-points cells were found in the gonads of some of the recipient embryos. The number of cells and the number of embryos showing stained PGCs in the gonads was inversely proportional to the age of the
- the recipient egg was positioned horizontally under a dissecting scope. A small hole was pierced into the air space of the egg to lower the internal pressure of the egg and prevent leakage. A 10 mm window was opened on the ventral surface of the egg and ⁇ 1 ml of PBS with 4% antibiotic/antimitotic was injected through the hole to bring the embryo up until it was slightly less than flush with the egg shell window. To inject the PGCs, a 30 ⁇ m pipet was beveled and then pulled using a micro forge to form a fine point with polished edges. Two hundred PGCs per embryo transfer, dissociated as described below, were picked up manually using a needle-pipette and a suction tube.
- Chicken PGCs are positive for periodic acid Schiff staining (PAS) and are claimed to be positive for alkaline phosphatase. However, there is no convincing evidence that chicken PGCs are positive for the latter.
- PAS periodic acid Schiff staining
- their phenotype was evaluated by transferring cells to recipient embryos and evaluating their presence in the gonads of the developing embryo. This method required culturing the PGCs in 100 ⁇ g/ml Dil in a ⁇ -MEM medium and rinsing prior to transfer to recipient embryos. Twenty-four hours post-transfer recipient embryos were removed and placed under an inverted microscope.
- Dil labeled cells observed in the gonads were interpreted as successful PGC migration to the gonads and confirmation of retention of PGC characteristics.
- a second method to evaluate the retention of the PGC phenotype was pursued by letting recipient embryos go to hatching and then evaluate the presence of donor PGCs in their gonads after breeding.
- the first strategy used recipient black feathered birds with possible genotype i/i, E/E, s/s, b/b and donor white feathered broiler type birds with genotype I/I, E/E, S/S, B/B.
- recipient animals were chimeric, that is to say that contain their own PGCs and donor PGCs in their gonads, they were mated to pure black feathered birds. If the resulting progeny was all black feathered then the animal was assumed to be non chimeric. However, if some of the progeny was white feathered with some black feathered patches then the recipient animal would be chimeric.
- Putative chimeric E/-(WB) birds when crossed to WB birds produced pure white chicks when they originated from a donor (WB) PGC and, white with black speckled feathers chicks when they originated from the (E/-) PGC.
- WB donor
- BR white-speckled black chicks when they originated from a (BR) PGCS.
- Crosses between putative BR chimeric birds were also done. For the latter, white chicks were produced when fertilization between two (WB) PGCs occurred and black chicks were the result of fertilization with two (BR) PGC.
- the intermediate white chick with speckled black feathers only happened when a (BR) PGC was fertilized by a (WB) PGC. LONG-TERM CULTURES BEYOND 25 DAYS
- PGC clumps form rapidly spreading monolayers. These monolayers of cell shave a flat adherent base and looser clumps and chains of PGC like cells on the upper surface. Some packets of these monolayers of cells remain PAS positive. Dil stained cells obtained from these monolayers have been transferred to recipient embryos. Some embryos have shown few cells localized in their gonads. Cell monolayers have been passaged successfully. Generally, these cells are capable of undergoing 3 to 5 passages before they start to slow down their proliferation, age and become fibroblastic looking. There are few cell lines that have gone through multiple passages and continue to thrive without apparent differentiation for about four months in continuous culture.
- Chimeric chickens were generated from fresh and cryopreserved PGCS. Twenty-five (74%) out of 34 putative chimeric chickens, produced with fresh PGCs transfers, proved to be true chimeric animals after progeny testing. Thirty (88%) out of 34 putative chimeric birds, produced with cryopreserved PGCs, were demonstrated to be true chimeric chickens. In all cases, at least 40 progeny were produced and the number of donor PGCs that were fertilized per chimeric bird varied from 1.4% to 100%, with the majority ranging between 30% to 60%. Assuming that the latter is a reflection of the number of PGCs that migrated to the gonad after injection, then the range of success per injection was varied.
- PGC phenotype under long term culture conditions After collection, PGCs are recognized by their size and by the presence of libid droplets in their cytoplasm. At about 48 hours after collection, PGCs clump together and start dividing as evidenced by the growth in size of the clump and the number of cells observed after trypsin dissociation of the clump. Only PGCs that form clumps survive, all others die. Generally, a culture starting with 100 PGCs would end up with an average of 600 to 800 PGCs within seven days. Clearly some PGCs divide, albeit not at an efficient rate. However, as indicated above, these PGCs maintain their ability to migrate to the gonads. LONG-TERM CULTURES BEYOND 25 DAYS
- PGC clumps form rapidly spreading monolayers. These monolayers of cells have a flat adherent base and looser clumps and chains of PGC like cells on the upper surface. Some packets of these monolayers of cells remain PAS positive. Dil stained cells obtained from these monolayers have been transferred to recipient embryos. Some embryos have shown few cells localized in their gonads. Cell monolayers have been passaged successfully. Generally, these cells are capable of undergoing 3 to 5 passages before they start to slow down their proliferation to age and become fibroblast-like in appearance. There are few cell lines that have gone through multiple passages and continue to thrive without apparent differentiation for about four months in continuous culture.
- P102896 and PI 10596 Two cell lines obtained from monolayers, P102896 and PI 10596, have been frozen. The former did not show apparent differentiation and was marginally positive for alkaline phosphatase while the latter showed neuronal cell morphology and was strongly positive for alkaline phosphatase. Further characterization of PGC monolayers as described here remains to be assessed for totipotency and pluripotency. In particular, it has been shown that PGCs cultured using the above four growth factors for at least 25 days can successfully colonize the gonads and produce chimeric chickens. Also, we have maintained PGC cells in culture for up to four months. These cultures still appear to comprise cells having the desired PGC phenotype. While these cells were not tested for their ability to produce chimeric birds, based on their appearance, it is expected that they should be useful therefor.
- PGC transfection Lipofection of a vector containing the green fluorescence protein reporter gene has been used for transfection of PGCS. On average 1/50 PGCs were transiently transfected, however, no stable transfected cell line has been developed yet.
- a PGC culture system should allow for transfection and selection of PGCs while maintaining the PGC ability to migrate to the gonads. Also, as disclosed in more detail in a related application (filed on even date), chicken PGCs, August 3, 1998after prolonged culturing, revert to the ES cell phenotype, as occurs with mouse PGCs (Matsui et al. Cell, 70:841-847, 1992). Therefore, injection of dispersed ES cells into recipient blastoderms should provide another means for the generation of chimeric and transgenic chickens.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU52483/99A AU5248399A (en) | 1998-08-03 | 1999-08-02 | Prolonged culturing of avian primordial germ cells using specific growth factorsand use thereof |
KR1020017001411A KR20020013461A (ko) | 1998-08-03 | 1999-08-02 | 특정 성장인자를 사용한 조류 원시배세포의 연장된 배양법및 이의 용도 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12762498A | 1998-08-03 | 1998-08-03 | |
US09/127,624 | 1998-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000008132A1 true WO2000008132A1 (en) | 2000-02-17 |
Family
ID=22431050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/017385 WO2000008132A1 (en) | 1998-08-03 | 1999-08-02 | Prolonged culturing of avian primordial germ cells using specific growth factors and use thereof |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR20020013461A (ko) |
AU (1) | AU5248399A (ko) |
WO (1) | WO2000008132A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1264889A1 (en) * | 2001-06-07 | 2002-12-11 | Hiroshima University | Chicken leukemia inhibitory factor (LIF) and the gene thereof |
CN111500531A (zh) * | 2020-05-15 | 2020-08-07 | 扬州大学 | 一种鸡PGCs在体外长期培养的方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100378747B1 (ko) * | 1999-02-11 | 2003-04-07 | 한미약품공업 주식회사 | 조류의 다능성 배자생식세포주 및 이의 제조방법 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5258307A (en) * | 1990-09-17 | 1993-11-02 | Merck & Co., Inc. | Single stage avian embryo culture process |
-
1999
- 1999-08-02 AU AU52483/99A patent/AU5248399A/en not_active Abandoned
- 1999-08-02 KR KR1020017001411A patent/KR20020013461A/ko not_active Application Discontinuation
- 1999-08-02 WO PCT/US1999/017385 patent/WO2000008132A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5258307A (en) * | 1990-09-17 | 1993-11-02 | Merck & Co., Inc. | Single stage avian embryo culture process |
Non-Patent Citations (1)
Title |
---|
PAIN ET AL: "Long-Term In Vitro Culture and Characterisation of Avian Embryonic Stem Cells with Multiple Morphogenetic Potentialities", DEVELOPMENT, vol. 122, August 1996 (1996-08-01), pages 2339 - 2348, XP002913043 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1264889A1 (en) * | 2001-06-07 | 2002-12-11 | Hiroshima University | Chicken leukemia inhibitory factor (LIF) and the gene thereof |
US7029664B2 (en) | 2001-06-07 | 2006-04-18 | Hiroshima University | Chicken leukemia inhibitory factor (LIF) |
US7250275B2 (en) | 2001-06-07 | 2007-07-31 | Hiroshima University | Nucleic acid encoding chicken leukemia inhibitory factor (LIF) |
US7619080B2 (en) | 2001-06-07 | 2009-11-17 | Hiroshima University | Oligonucleotides of a chicken leukemia inhibitory factor (LIF) gene |
US7691589B2 (en) | 2001-06-07 | 2010-04-06 | Hiroshima University | Method of preventing differentiation of a chicken differentiable cell using chicken leukemia inhibitory factor (LIF) |
CN111500531A (zh) * | 2020-05-15 | 2020-08-07 | 扬州大学 | 一种鸡PGCs在体外长期培养的方法 |
Also Published As
Publication number | Publication date |
---|---|
AU5248399A (en) | 2000-02-28 |
KR20020013461A (ko) | 2002-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6156569A (en) | Prolonged culturing of avian primordial germ cells (PGCs) using specific growth factors, use thereof to produce chimeric avians | |
EP1007633B1 (en) | Avian primordial germ cell (pgc) cell line and a method for long term culturing thereof | |
AU738357B2 (en) | Production of avian embryonic germ (EG) cell lines by prolonged culturing of PGCS, use thereof for cloning and chimerization | |
US20140127812A1 (en) | Long-term culture of avian primordial germ cells (pgcs) | |
JP2002536012A (ja) | 鳥類の多能性胚性生殖細胞株 | |
US6703209B1 (en) | Porcine totipotent cells and method for long-term culture | |
JP2007501625A (ja) | 鳥類精原幹細胞の培養方法及びこれにより収得した鳥類精原幹細胞 | |
US20050244958A1 (en) | Production of avian embryonic germ (EG) cell lines by prolonged culturing of PGCs, use thereof for cloning and chimerization | |
US7476776B2 (en) | Method for improving germline transmission efficiency of avian primordial germ cells | |
US20020162134A1 (en) | Primordial germ cell-based germ line production of birds | |
WO2000008132A1 (en) | Prolonged culturing of avian primordial germ cells using specific growth factors and use thereof | |
US20070044167A1 (en) | Method for producing avian chimera using spermatogonial cells and avian chimera | |
CA2438612A1 (en) | Primordial germ cell-based germ line production of birds | |
MXPA00001301A (en) | Avian primordial germ cell (pgc) cell line and a method for long term culturing thereof | |
KR100267633B1 (ko) | 배양된 원시생식세포로 전이된 생식선 키메라 조류의 생산방법 | |
MXPA00001300A (en) | Production of avian embryonic germ (eg) cell lines by prolonged culturing of pgcs, use thereof for cloning and chimerization | |
CN118147052A (zh) | 分离、培养鸡原始生殖干细胞并构建基因修饰鸡的方法 | |
한재용 et al. | Expression of Lac Z gene in young chick gonad by the transfected primordial germ cell injection | |
AU2002253850A1 (en) | Primordial germ cell-based germ line production of birds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020017001411 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 1020017001411 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020017001411 Country of ref document: KR |